RTSL Statistics
Total Valuation
Rapid Therapeutic Science Laboratories has a market cap or net worth of 30,379. The enterprise value is 3.81 million.
| Market Cap | 30,379 |
| Enterprise Value | 3.81M |
Important Dates
The next estimated earnings date is Friday, March 14, 2025.
| Earnings Date | Mar 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Rapid Therapeutic Science Laboratories has 18.99 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 18.99M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +4.24% |
| Owned by Insiders (%) | 24.19% |
| Owned by Institutions (%) | 2.88% |
| Float | 12.90M |
Valuation Ratios
The trailing PE ratio is 0.21.
| PE Ratio | 0.21 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 64.04 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -15.20 |
Financial Position
The company has a current ratio of 0.07
| Current Ratio | 0.07 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -15.09 |
| Interest Coverage | -0.79 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -12.91% |
| Return on Capital (ROIC) | -35.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | 14,889 |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.17% in the last 52 weeks. The beta is -11.60, so Rapid Therapeutic Science Laboratories's price volatility has been lower than the market average.
| Beta (5Y) | -11.60 |
| 52-Week Price Change | -79.17% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.61 |
| Relative Strength Index (RSI) | 44.79 |
| Average Volume (20 Days) | 141,214 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 67.89 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -465,062 |
| Pretax Income | 59,556 |
| Net Income | 59,556 |
| EBITDA | -441,090 |
| EBIT | -465,062 |
| Earnings Per Share (EPS) | 0.01 |
Balance Sheet
The company has 2,160 in cash and 3.79 million in debt, giving a net cash position of -3.78 million or -0.20 per share.
| Cash & Cash Equivalents | 2,160 |
| Total Debt | 3.79M |
| Net Cash | -3.78M |
| Net Cash Per Share | -0.20 |
| Equity (Book Value) | -2.74M |
| Book Value Per Share | -0.31 |
| Working Capital | -4.11M |
Cash Flow
In the last 12 months, operating cash flow was -566,601 and capital expenditures 315,645, giving a free cash flow of -250,956.
| Operating Cash Flow | -566,601 |
| Capital Expenditures | 315,645 |
| Free Cash Flow | -250,956 |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Rapid Therapeutic Science Laboratories does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.64% |
| Shareholder Yield | -2.64% |
| Earnings Yield | 468.25% |
| FCF Yield | -826.08% |
Stock Splits
The last stock split was on March 31, 2022. It was a reverse split with a ratio of 0.04.
| Last Split Date | Mar 31, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.04 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |